Quantum BioPharma wins FDA clearance for Lucid-MS pivotal Phase 2 trial in progressive multiple sclerosis

Reuters2026/08/14 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quantum BioPharma received FDA clearance on Aug. 10, 2026 to start a pivotal Phase 2 Lucid-MS trial in progressive multiple sclerosis.
Results have not been presented; the randomized, double-blind, placebo-controlled study will generate future clinical data.
The trial advances a patented neuroprotective program into the next development stage, targeting a high unmet-need segment in multiple sclerosis.
Liquidity as of Q2 2026 stood at about US$9.5 million, supporting planned operations through at least October 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005524), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quantum BioPharma wins FDA clearance for Lucid-MS pivotal Phase 2 trial in progressive multiple sclerosis

You may also like

Crypto prices